138 related articles for article (PubMed ID: 21698837)
21. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
23. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
[TBL] [Abstract][Full Text] [Related]
24. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
25. An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers.
Everly MJ
Clin Transpl; 2010; ():353-62. PubMed ID: 21696053
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
28. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
30. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
31. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
[TBL] [Abstract][Full Text] [Related]
32. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
34. Prospective iterative trial of proteasome inhibitor-based desensitization.
Woodle ES; Shields AR; Ejaz NS; Sadaka B; Girnita A; Walsh RC; Alloway RR; Brailey P; Cardi MA; Abu Jawdeh BG; Roy-Chaudhury P; Govil A; Mogilishetty G
Am J Transplant; 2015 Jan; 15(1):101-18. PubMed ID: 25534446
[TBL] [Abstract][Full Text] [Related]
35. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
[TBL] [Abstract][Full Text] [Related]
36. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports.
Wong W; Lee RA; Saidman SL; Smith RN; Zorn E
Clin Transpl; 2009; ():401-5. PubMed ID: 20524305
[TBL] [Abstract][Full Text] [Related]
39. A summary of bortezomib use in transplantation across 29 centers.
Everly MJ
Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
[TBL] [Abstract][Full Text] [Related]
40. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
